¼¼°èÀÇ ¹Ì½ê¶ó(Mircera) ½ÃÀå º¸°í¼­(2025³â) : ¿ªÇÐ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ½ÃÀå ÀλçÀÌÆ® ¹× ¿¹Ãø
Mircera Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
»óǰÄÚµå : 1763080
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,290,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,091,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,893,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì½ê¶ó ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº Àü ¼¼°èÀûÀ¸·Î, ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í, ½ÅÈï ½ÃÀåÀ» Áß½ÉÀ¸·Î ÀÇ·áºñ ÁöÃâÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºóÇ÷À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô°í, ºóÇ÷ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí, ¹Ì½ê¶ó°¡ º´¿ø°ú ¿Ü·¡ ȯÀÚ È¯°æ ¸ðµÎ¿¡¼­ äÅÃµÉ °ÍÀ¸·Î ¿¹»óµÇ±â ¶§¹®ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Àå±â°£ ÀÛ¿ëÇü ESA¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú ¹ßÀü, ÀÇ·á ÀÎÇÁ¶ó °³¹ß, ¸¸¼º ½ÅÀå Áúȯ(CKD) °ü¸®¿¡ ´ëÇÑ Ã¤Åà Áõ°¡, ȯÀÚ Á᫐ ÀǾàǰ Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼º ½ÅÀå Áúȯ(CKD)ÀÇ À¯º´·ü Áõ°¡´Â ¾ÕÀ¸·Î ¹Ì½ê¶ó ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CKD´Â ½ÅÀå ±â´ÉÀÌ Á¡ÁøÀûÀ¸·Î »ó½ÇµÇ´Â °Ç°­ ¹®Á¦À̸ç, Á¾Á¾ ´ç´¢º´ ¹× °íÇ÷¾Ð°ú °°Àº Áúȯ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. CKDÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÏ´Â ¿äÀÎÀº Àα¸ °í·ÉÈ­, »ýȰ ¹æ½ÄÀÇ º¯È­, Áø´Ü ±â¼úÀÇ ¹ßÀü µîÀÔ´Ï´Ù. ÀûÇ÷±¸ »ý¼º È£¸£¸óÀÇ »ý»ê °¨¼Ò·Î ÀÎÇØ ¹ß»ýÇÏ´Â CKDÀÇ ÈçÇÑ ÇÕº´ÁõÀÎ ºóÇ÷À» Ä¡·áÇϰí Çì¸ð±Û·Îºó ¼öÄ¡¸¦ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöÇϱâ À§Çؼ­´Â ¹Ì½ê¶ó¿Í °°Àº ÀûÇ÷±¸ »ý¼º ÃËÁøÁ¦°¡ ÇÊ¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 6¿ù ¿µ±¹ ½ÅÀå ¿¬±¸¼Ò(Kidney Research UK)¿¡ µû¸£¸é, ¿µ±¹¿¡´Â ¾à 720¸¸ ¸íÀÇ CKD ȯÀÚ°¡ ÀÖÀ¸¸ç, 2033³â¿¡´Â ±× ¼ö°¡ 761¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ CKDÀÇ À¯º´·ü Áõ°¡´Â ¹Ì½ê¶ó ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹Ì½ê¶ó ½ÃÀåÀÇ ÁÖ¿ä µ¿ÇâÀº CKD¿Í °ü·ÃµÈ ºóÇ÷ Ä¡·á¸¦ À§ÇØ, ƯÈ÷ ¼Ò¾Æ ȯÀÚ¸¦ À§ÇÑ ½ÂÀÎµÈ ¼Ö·ç¼Ç °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. CKD·Î ÀÎÇÑ ºóÇ÷ÀÌ ÀÖ´Â ¼Ò¾Æ ȯÀÚ´Â ÀûÇ÷±¸ »ý¼ºÀ» ÃËÁøÇÏ´Â Àå±â°£ ÀÛ¿ëÇü ÀûÇ÷±¸ »ý¼º ÃËÁøÁ¦ÀÎ ¹Ì½ê¶ó(¸ÞÅå½Ã Æú¸®¿¡Æ¿·» ±Û¸®ÄÝ-¿¡Æ÷¿¡Æ¾ º£Å¸)ÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÚÁÖ Áֻ縦 ¸ÂÀ» Çʿ伺À» ÁÙÀ̰í Ç÷¾× ¼öÇ÷ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸç Çì¸ð±Û·Îºó ¼öÄ¡¸¦ °³¼±ÇØ Àü¹ÝÀûÀÎ ¼ºÀå°ú »îÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 4¿ù Vifor Pharma´Â ¹Ì½ê¶ó¸¦ CKD °ü·Ã ºóÇ÷ Ä¡·á¿¡ »ç¿ëÇϱâ À§ÇØ 3°³¿ù¿¡¼­ 17¼¼ »çÀÌÀÇ ¼Ò¾Æ ȯÀÚ¸¦ ´ë»óÀ¸·Î FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ½ÂÀÎÀº Åõ¼® ȯÀÚ ¹× ºñÅõ¼® ȯÀÚ ¸ðµÎ¿¡°Ô Àû¿ëµÇ¸ç, ƯÈ÷ ´Ù¸¥ ESA¿¡¼­ ÀüȯÇϴ ȯÀÚ¿¡°Ô ƯÈ÷ Àû¿ëµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå¿¡¼­ÀÇ Á¦Ç° Ư¼º

Á¦4Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦5Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°, °æ±â ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦7Àå ¼¼°è ½ÃÀåÀÇ °¡°Ý ºÐ¼®°ú ¿¹Ãø

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­

Á¦9Àå ÀÓ»óÀûÀÀÁõ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦10Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦12Àå Áß±¹ ½ÃÀå

Á¦13Àå Àεµ ½ÃÀå

Á¦14Àå ÀϺ» ½ÃÀå

Á¦15Àå È£ÁÖ ½ÃÀå

Á¦16Àå Çѱ¹ ½ÃÀå

Á¦17Àå ¼­À¯·´ ½ÃÀå

Á¦18Àå ¿µ±¹ ½ÃÀå

Á¦19Àå µ¶ÀÏ ½ÃÀå

Á¦20Àå ÇÁ¶û½º ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ºÏ¹Ì ½ÃÀå

Á¦23Àå ¹Ì±¹ ½ÃÀå

Á¦24Àå ij³ª´Ù ½ÃÀå

Á¦25Àå ³²¹Ì ½ÃÀå

Á¦26Àå Áßµ¿ ½ÃÀå

Á¦27Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦28Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦29Àå ¼¼°è ½ÃÀå : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦30Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦31Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦32Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦33Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦34Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Mircera is a medication designed to treat anemia associated with chronic kidney disease (CKD) and anemia in cancer patients. As a long-acting erythropoiesis-stimulating agent (ESA), it works by stimulating red blood cell production to maintain healthy hemoglobin levels. Its extended dosing schedule, typically requiring injections once every two to four weeks, makes it convenient for patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulation types of mircera include injectable solutions and pre-filled syringes. These formulations are used to treat anemia resulting from chronic kidney disease and cancer-related anemia. Mircera is distributed through hospitals, dialysis centers, specialty clinics, and retail pharmacies. The medication serves various end-users, including adult and geriatric patients.

The mircera market research report is one of a series of new reports from The Business Research Company that provides mircera market statistics, including mircera industry global market size, regional shares, competitors with a mircera market share, detailed mircera market segments, market trends and opportunities, and any further data you may need to thrive in the mircera industry. This mircera market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mircera market size is expected to see strong growth in the next few years. It will grow to $3,506.3 million in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to the expected rise in the global cancer burden, particularly in developing regions, continued increase in healthcare expenditure, particularly in emerging markets, high demand for innovative treatment options to manage anemia more effectively, increasing demand for anemia treatments, adoption of Mircera in both hospital and outpatient settings. Major trends in the forecast period include rising demand for long-acting ESAs, technological advancements, healthcare infrastructure development, increasing adoption in chronic kidney disease (CKD) management, and increasing focus on patient-centric drug delivery systems.

The rising prevalence of chronic kidney disease (CKD) is expected to propel the growth of the mircera market going forward. CKD is a health concern characterized by the gradual loss of kidney function, often associated with conditions such as diabetes and hypertension. The increasing incidence of CKD is driven by factors such as aging populations, lifestyle changes, and improved diagnostic practices. Anemia, a common complication of CKD caused by reduced erythropoietin production, necessitates the use of erythropoiesis-stimulating agents like Mircera to manage and stabilize hemoglobin levels. For instance, in June 2023, according to Kidney Research UK, approximately 7.2 million people in the UK are living with CKD, and by 2033, the number is expected to rise to 7.61 million. Therefore, the rising prevalence of CKD drives the growth of the mircera market.

A key trend in the mircera market is focusing on developing approved solutions, particularly for pediatric patients, for the treatment of anemia associated with CKD. Pediatric patients with anemia due to CKD can benefit from Mircera (methoxy polyethylene glycol-epoetin beta), a long-acting erythropoiesis-stimulating agent that helps stimulate red blood cell production. This reduces the need for frequent injections, minimizes the risk of blood transfusions, and improves hemoglobin levels, enhancing overall growth and quality of life. For instance, in April 2024, Vifor Pharma received FDA approval to include pediatric patients aged 3 months to 17 years for Mircera's use in treating CKD-related anemia. This approval applies to both dialysis and non-dialysis patients, especially those transitioning from another ESA.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma, the developer of Mircera. This acquisition aims to expand CSL's presence in the nephrology space and enhance its portfolio of treatments for anemia in CKD patients.

The Key player operating in the mircera market is Roche

North America was the largest region in the mircera market in 2024. The regions covered in mircera report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mircera market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mircera market consists of sales of solutions and pre-filled syringes designed to treat anemia caused by chronic kidney disease (CKD). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mircera Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mircera market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for mircera ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mircera market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Mircera Market Characteristics

3. Mircera Market Biologic Drug Characteristics

4. Mircera Market Trends And Strategies

5. Mircera Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Mircera Growth Analysis And Strategic Analysis Framework

7. Global Mircera Market Pricing Analysis & Forecasts

8. Mircera Market Segmentation

9. Global Mircera Market Epidemiology Of Clinical Indications

10. Mircera Market Regional And Country Analysis

11. Asia-Pacific Mircera Market

12. China Mircera Market

13. India Mircera Market

14. Japan Mircera Market

15. Australia Mircera Market

16. South Korea Mircera Market

17. Western Europe Mircera Market

18. UK Mircera Market

19. Germany Mircera Market

20. France Mircera Market

21. Eastern Europe Mircera Market

22. North America Mircera Market

23. USA Mircera Market

24. Canada Mircera Market

25. South America Mircera Market

26. Middle East Mircera Market

27. Africa Mircera Market

28. Mircera Market Competitive Landscape And Company Profiles

29. Global Mircera Market Pipeline Analysis

30. Global Mircera Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Mircera Market

32. Recent Developments In The Mircera Market

33. Mircera Market High Potential Countries, Segments and Strategies

34. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â